Home Cart Sign in  
Chemical Structure| 295-64-7 Chemical Structure| 295-64-7

Structure of 295-64-7

Chemical Structure| 295-64-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 295-64-7 ]

CAS No. :295-64-7
Formula : C10H25N5
M.W : 215.34
SMILES Code : N1CCNCCNCCNCCNCC1
MDL No. :MFCD00195482
InChI Key :KDCBVVQAMMXRFB-UHFFFAOYSA-N
Pubchem ID :120196

Safety of [ 295-64-7 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H319
Precautionary Statements:P305+P351+P338

Computational Chemistry of [ 295-64-7 ] Show Less

Physicochemical Properties

Num. heavy atoms 15
Num. arom. heavy atoms 0
Fraction Csp3 1.0
Num. rotatable bonds 0
Num. H-bond acceptors 5.0
Num. H-bond donors 5.0
Molar Refractivity 81.65
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

60.15 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.88
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

-2.79
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

-3.96
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-1.04
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.0
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

-1.18

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

0.58
Solubility 824.0 mg/ml ; 3.82 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Highly soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

2.08
Solubility 25900.0 mg/ml ; 120.0 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Highly soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.93
Solubility 0.254 mg/ml ; 0.00118 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

Low
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

Yes
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-9.59 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.29

Application In Synthesis of [ 295-64-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 295-64-7 ]

[ 295-64-7 ] Synthesis Path-Downstream   1~35

  • 3
  • [ 295-64-7 ]
  • [ 24463-19-2 ]
  • [ 126257-27-0 ]
  • 4
  • [ 295-64-7 ]
  • [ 5339-26-4 ]
  • [ 1879-55-6 ]
  • 1,4,7,10,13-pentaaza-1-N-(2-(4-nitrophenyl)ethyl)cyclopentadecane [ No CAS ]
  • 1,4-Bis-[2-(4-nitro-phenyl)-ethyl]-1,4,7,10,13-pentaaza-cyclopentadecane [ No CAS ]
  • 5
  • [ 295-64-7 ]
  • [ 130707-89-0 ]
  • 1,4,7,10,13-pentaaza-1-N-(1-carboisopropoxy-3-(4-nitrophenyl)propyl)cyclopentadecane [ No CAS ]
  • 6
  • [ 295-64-7 ]
  • [ 77-92-9 ]
  • 1,4,7,10,13-Pentaaza-cyclopentadecane; compound with 3-carboxy-3-hydroxy-pentanedioic acid [ No CAS ]
  • 7
  • [ 295-64-7 ]
  • [ 501-53-1 ]
  • mono(benzyloxycarbonyl)-1,4,7,10,13-pentaazacyclopentadecane [ No CAS ]
  • [ 195062-20-5 ]
  • 1,4,7,10,13-pentakis(benzyloxycarbonyl)-1,4,7,10,13-pentaazacyclopentadecane [ No CAS ]
  • 8
  • [ 295-64-7 ]
  • [ 5292-43-3 ]
  • 1,4,7,10,13-pentakis(tert-butoxycarbonylmethyl)-1,4,7,10,13-pentaazacyclopentadecane [ No CAS ]
YieldReaction ConditionsOperation in experiment
31% E. Synthesis of 1,4,7,10,13-Pentaazacyclopentadecane A mixture of 1,4,7,10,13-penta(p-toluenesulfonyl)-1,4,7,10,13-pentaazacyclopentadecane prepared as in Example 1D (168 g, 0.170 mole) and concentrated H2 SO4 (500 ml) was heated at 100 C. with stirring under a dry argon atmosphere for 70 h. To the resulting dark brown solution ethanol (500 ml) was added dropwise with stirring at 0 C. followed by ethyl ether (3 l). The white solid was filtered and washed with ethyl ether. The solid was then dissolved in H2 O (500 ml) and the resulting solution washed with ethyl ether. Upon reducing the volume of the solution in vacuo to 200 ml, the pH was adjusted to 10-11 with 10N NaOH and the solvent was removed in vacuo. Ethanol (500 ml) was then added and removed in vacuo to dryness. The resulting tan oily solid was extracted with hot THF (2*500 ml) and filtered at room temperature. The filtrates were combined and the solvent removed in vacuo to give the crude product as a yellow crystalline solid which was then redissolved in CH3 CN and filtered to remove insoluble impurities. Recrystallization from cold (-20 C.) CH3 CN gave 11.3 g (31% yield) of the product as colorless needles: mp 108-9 C.; 1 H NMR (CDCl3) delta 1.74 (br s, 5 H), 2.73 (s, 20 H); Exact mass (M+Li)+: calcd, 222.2270; Found, 222.2269 (C10 H25 N5 Li).
31% E. Synthesis of 1,4,7,10,13-Pentaazacyclopentadecane A mixture-of 1,4,7,10,13-penta(p-toluenesulfonyl)-1,4,7,10,13-pentaazacyclopentadecane prepared as in Example 1D (168 g, 0.170 mole) and concentrated H2 SO4 (500 ml) was heated at 100 C. with stirring under a dry argon atmosphere for 70 h. To the resulting dark brown solution ethanol (500 ml) was added dropwise with stirring at 0 C. followed by ethyl ether (3 l). The white solid was filtered and washed with ethyl ether. The solid was then dissolved in H2 O (500 ml) and the resulting solution washed with ethyl ether. Upon reducing the volume of the solution in vacuo to 200 ml, the pH was adjusted to 10-11 with 10N NaOH and the solvent was removed in vacuo. Ethanol (500 ml) was then added and removed in vacuo to dryness. The resulting tan oily solid was extracted with hot THF (2*500 ml) and filtered at room temperature. The filtrates were combined and the solvent removed in vacuo to give the crude product as a yellow crystalline solid which was then redissolved in CH3 CN and filtered to remove insoluble impurities. Recrystallization from cold (-20 C.) CH3 CN gave 11.3 g (31% yield) of the product as colorless needles: mp 108-9 C.; 1 H NMR (CDCl3) delta1.74 (br s, 5 H), 2.73 (s, 20 H); Exact mass (M+Li)+: calcd, 222.2270; Found, 222.2269 (C10 H25 N5 Li).
Further preferred cascade starters A(H)b that can be listed are, inter alia: ... 1,3,5-tris(aminomethyl)benzene (b=6); 2,4,6-tris(aminomethyl)pyridine (b=6); 1,4,7-triazacyclononane (b=3); 1,4,7,10-tetraazacyclododecane (b=4); 1,4,7,10,13-pentaazacyclopentadecane (b=5); 1,4,8,11-tetraazacyclotetradecane (b=4); 1,4,7,10,13,16,19,22,25,28-decaazacyclotriacontane (b=10); 6,6',6",6"',6"",6""'-hexa-(1-amino-2-hydroxypropyl)-alpha-cyclodextrin hexaether (b=12); ...
  • 11
  • [ 295-64-7 ]
  • [ 3720-84-1 ]
  • 1-(3-triethylammonio)propyl-1,4,7,10,13-penta-azacyclopentadecane [ No CAS ]
  • 12
  • [ 295-64-7 ]
  • [ 89972-78-1 ]
  • [ 354112-18-8 ]
  • 13
  • [ 295-64-7 ]
  • [ 3705-42-8 ]
  • 1,4,7,10,13-pentakis[4'-(N-benzyloxycarbonyl)amino-4'-benzyloxycarbonylbutanoyl]pentaazacyclopentadecane [ No CAS ]
  • 14
  • [ 295-64-7 ]
  • [ 57294-38-9 ]
  • [ 266000-49-1 ]
  • 15
  • [ 295-64-7 ]
  • [ 16977-78-9 ]
  • acetic acid 3,5-diacetoxy-2-acetoxymethyl-6-[2-(1,4,7,10,13pentaaza-cyclopentadec-1-yl)-ethoxy]-tetrahydro-pyran-4-yl ester [ No CAS ]
  • 16
  • [ 295-64-7 ]
  • 1-(2-ethoxy-β-D-galactopyranosyl)-1,4,7,10,13-pentaazacyclopentadecane [ No CAS ]
  • 21
  • [ 295-64-7 ]
  • [ 3720-84-1 ]
  • [ 316147-15-6 ]
YieldReaction ConditionsOperation in experiment
10 mmol of (3-bromopropyl)triethylammonium bromide are added to 10 mmol of [15ane]-N5(*) dissolved in 50 ml of deionised water.. After heating at 90 C. for 12 hours under an inert atmosphere, the water is evaporated off.. The oily residue is washed twice with dichloromethane and then dissolved in 100 ml of ethanol.. Treatment with 4 ml of 10N HCl added dropwise, while cooling the balloon flask to 0 C., yields a flaky white precipitate which is filtered, washed with alcohol and then with ether and dried, yielding the expected product. Melting point: >200 C. (decomposition)
YieldReaction ConditionsOperation in experiment
A 58.3-g sample of the pentatosyl derivative of 1,4,7,10,13-pentaazacyclopentadecane prepared as described was dissolved in 120 ml of concentrated sulfuric acid and the solution heated at 100 for 4 hours, at which time a sample gave a clear solution in water made basic with sodium hydroxide. The product was precipitated by the addition of 300 ml of ether, and the off-white solid separated by filtration (nitrogen atmosphere). The solid was slurried in 100 ml of water and 75 ml of 50% sodium hydroxide solution was added to effect separation of an oil. The mixture was continuously extracted with benzene, the benzene layer separated and the solvent evaporated to leave 7.15 g of 1,4,7,10,13-pentaazacyclopentadecane, mp 92-103. The product was purified by sublimation at 90-95 (5mu), and it was obtained in the form of long white electrostatic needles (5.0 g). The solid is hygroscopic. Anal. Calcd for C10 H15 N5: C, 55.78; H, 11.70; N, 32.52 Found: C, 54.74; H, 11.16; N, 32.52.
  • 23
  • [ 295-64-7 ]
  • copper(II) perchlorate hexahydrate [ No CAS ]
  • (C10N5H25)*Cu(2+)*2ClO4(1-) = (C10N5H25)Cu(ClO4)2 [ No CAS ]
  • 24
  • [ 295-64-7 ]
  • silver nitrate [ No CAS ]
  • [ 131362-29-3 ]
  • 25
  • [ 295-64-7 ]
  • sodium perchlorate [ No CAS ]
  • cobalt(II) perchlorate hexahydrate [ No CAS ]
  • μ-peroxo-bis(1,4,7,10,13-pentaazacyclopentadecane)dicobalt(III) perchlorate monohydrate [ No CAS ]
  • 26
  • [ 295-64-7 ]
  • nickel(II) perchlorate hexahydrate [ No CAS ]
  • {Ni(1,4,7,10,13-pentaazacyclopentadecane)}(ClO4)2 [ No CAS ]
  • 27
  • [ 295-64-7 ]
  • bromopentaaminecobalt(III) bromide [ No CAS ]
  • [ 7550-35-8 ]
  • γ-bromo(1,4,7,10,13-pentaazacyclopentadecane)cobalt(III) bromide monohydrate [ No CAS ]
  • 28
  • cobalt(II) chloride hexahydrate [ No CAS ]
  • [ 295-64-7 ]
  • α and γ-chloro(1,4,7,10,13-pentaazacyclopentadecane)cobalt(III) chloride [ No CAS ]
  • 29
  • cobalt(II) chloride hexahydrate [ No CAS ]
  • [ 295-64-7 ]
  • α and γ-chloro(1,4,7,10,13-pentaazacyclopentadecane)cobalt(III) tetrachlorozincate(II) hemihydrate [ No CAS ]
  • 30
  • [ 295-64-7 ]
  • copper(II) nitrate [ No CAS ]
  • {Cu(1,4,7,10,13-pentaazacyclopentadecane)}(NO3)2 [ No CAS ]
  • 31
  • [ 295-64-7 ]
  • copper(II) perchlorate [ No CAS ]
  • {Cu(1,4,7,11,14-pentaazacyclopentadecane)}(ClO4)2 [ No CAS ]
  • 32
  • [ 295-64-7 ]
  • nickel(II) perchlorate [ No CAS ]
  • {Ni(1,4,7,10,13-pentaazacyclopentadecane)}(ClO4)2 [ No CAS ]
  • 33
  • [ 295-64-7 ]
  • [ 13859-51-3 ]
  • α and γ-chloro(1,4,7,10,13-pentaazacyclopentadecane)cobalt(III) tetrachlorozincate(II) hemihydrate [ No CAS ]
  • 34
  • [ 295-64-7 ]
  • [ 13820-81-0 ]
  • [ 82288-45-7 ]
  • (Co(cpad)H2O)(ClO4)2 [ No CAS ]
  • 35
  • [ 295-64-7 ]
  • nickel(II) nitrate [ No CAS ]
  • {Ni(1,4,7,10,13-pentaazacyclopentadecane)}(NO3)2 [ No CAS ]
 

Historical Records